A longitudinal study on a-synuclein in blood plasma as a biomarker for Parkinson's disease

Penelope G. Foulds, Peter Diggle, J. Douglas Mitchell, Angela Parker, Masato Hasegawa, Masami Masuda-Suzukake, David M A Mann, David Allsop

Research output: Contribution to journalArticle

Abstract

There have been no longitudinal studies on a-synuclein as a potential biomarker for the progression of Parkinson's disease (PD). Here, blood plasma 'total a-synuclein' and 'Ser-129 phosphorylated α-synuclein' were assayed at 4-6 monthly intervals from a cohort of 189 newly-diagnosed patients with PD. For log-transformed data, plasma total a-synuclein levels increased with time for up to 20 yrs after the appearance of initial symptoms (p 5 0.012), whereas phosphorylated α-synuclein remained constant over this same period. The mean level of phosphorylated a-synuclein, but not of total a-synuclein, was higher in the PD plasma samples taken at first visit than in single samples taken from a group of 91 healthy controls (p50.012). Overall, we conclude that the plasma level of phosphorylated α-synuclein has potential value as a diagnostic tool, whereas the level of total a-synuclein could act as a surrogate marker for the progression of PD.

Original languageEnglish (US)
Article number2540
JournalScientific Reports
Volume3
DOIs
StatePublished - Aug 29 2013
Externally publishedYes

ASJC Scopus subject areas

  • General

Fingerprint Dive into the research topics of 'A longitudinal study on a-synuclein in blood plasma as a biomarker for Parkinson's disease'. Together they form a unique fingerprint.

  • Cite this

    Foulds, P. G., Diggle, P., Mitchell, J. D., Parker, A., Hasegawa, M., Masuda-Suzukake, M., Mann, D. M. A., & Allsop, D. (2013). A longitudinal study on a-synuclein in blood plasma as a biomarker for Parkinson's disease. Scientific Reports, 3, [2540]. https://doi.org/10.1038/srep02540